US Pharma MarketingOncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.
Cancer still dominates pharma R&D. Obesity is gaining ground.
Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.
Source: PharmaVoice